1. Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.
- Author
-
Zhang DS, Bao XP, Zhu JJ, Zheng WJ, and Sun LX
- Subjects
- Adolescent, Child, Female, Humans, Male, China, Myalgia chemically induced, Parents, Surveys and Questionnaires, Vaccination adverse effects, Vaccines, Inactivated adverse effects, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated immunology, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines adverse effects, COVID-19 Vaccines administration & dosage
- Abstract
Our study aimed to evaluate the safety of CoronaVac, an inactivated vaccine made by Sinovac, in children aged 7-14. We conducted a parent-administered online survey to monitor adverse reactions after vaccinating children in Taizhou, China, from February 15, 2021, to January 19, 2022. 767 parents completed the survey after receiving a questionnaire via WeChat. Overall, 15.3 % (117/767) of children experienced adverse effects after the first dose, and 12.2 % (88/724) after the second. Muscle pain was the most common adverse reaction post-first dose (10.0 %), while localized pain or itching at the injection site was most common after the second dose (7.6 %). In conclusion, the vaccine has a low incidence of side effects. The mild to moderate, transient, and common nature of these effects further boosts parents' confidence in vaccinating their children., Competing Interests: Declaration of competing interest The authors declare that they have no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF